Literature DB >> 15566744

Detection of anti-HIV in saliva and urine at the time of seroconversion.

J A Connell1, J V Parry.   

Abstract

To determine whether there is a delay between the appearance of anti-HIV in serum/plasma and its detection in saliva and urine, salivary and urine specimens were collected from nine individuals who, on the basis of increasing IgG anti-HIV reactivity, Western blot band patterns and presence of strong IgM anti-HIV reactivity in their serum specimens, were believed to have recently become anti-HIV-positive. Serum from 8 of these patients and 3 commercial panels of plasma specimens collected during seroconversion were diluted to mimic the low immunoglobulin concentrations present in saliva and urine and tested in Wellcozyme HIV 1 + 2 GACELISA and four commercial EIAs intended for testing serum specimens. The 9 pairs of saliva and urine specimens were collected between 4 and 43 days (median 24 days) after the first evidence of seroconversion. All were reactive by Wellcozyme HIV 1 + 2 GACELISA and gave optical density/cut off (OD/CO) ratios in the range 3.8 to 9.8 (median 5.2) for dribbled saliva and 2.4 to 10.1 (median 6.3) for urine. Salivary specimens taken with commercial collection devices gave OD/CO ratios in the range 1.6 to 10.6 (median 5.9). In the serum/plasma specimens Wellcozyme HIV 1 + 2 GACELISA detected anti-HIV at higher dilutions than the other assays, often with a 100-fold or more difference. Saliva and urine specimens were all strongly reactive by Wellcozyme HIV 1 + 2 GACELISA. We therefore predict that it would first detect anti-HIV in salivary and urine specimens at about the same time as it becomes detectable in serum/plasma but that other commercial EIAs would not.

Entities:  

Year:  1994        PMID: 15566744     DOI: 10.1016/0928-0197(94)90060-4

Source DB:  PubMed          Journal:  Clin Diagn Virol        ISSN: 0928-0197


  8 in total

1.  A simple saliva-based test for detecting antibodies to human immunodeficiency virus.

Authors:  W Schramm; G B Angulo; P C Torres; A Burgess-Cassler
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

Review 2.  Detection of human immunodeficiency virus antibodies in oral fluids.

Authors:  R L Hodinka; T Nagashunmugam; D Malamud
Journal:  Clin Diagn Lab Immunol       Date:  1998-07

3.  Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey.

Authors:  S Allwright; F Bradley; J Long; J Barry; L Thornton; J V Parry
Journal:  BMJ       Date:  2000-07-08

4.  Human immunodeficiency virus antibody testing by enzyme-linked fluorescent and western blot assays using serum, gingival-crevicular transudate, and urine samples.

Authors:  P M Martínez; A R Torres; R Ortiz de Lejarazu; A Montoya; J F Martín; J M Eiros
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

5.  Detection of antibodies to human immunodeficiency virus type 1 in oral fluids: a large-scale evaluation of immunoassay performance.

Authors:  T C Granade; S K Phillips; B Parekh; P Gomez; W Kitson-Piggott; H Oleander; B Mahabir; W Charles; S Lee-Thomas
Journal:  Clin Diagn Lab Immunol       Date:  1998-03

6.  Oral fluid as a specimen for detection and confirmation of antibodies to human immunodeficiency virus type 1.

Authors:  T C Granade; S K Phillips; B Parekh; C P Pau; J R George
Journal:  Clin Diagn Lab Immunol       Date:  1995-07

Review 7.  Urinary immunoglobulins in viral diagnosis: An overview.

Authors:  Sreelekshmy Mohandas; Sudeep Balan; Devendra T Mourya
Journal:  Indian J Med Res       Date:  2022-01       Impact factor: 5.274

8.  Improving survey methods in sero-epidemiological studies of injecting drug users: a case example of two cross sectional surveys in Serbia and Montenegro.

Authors:  Ali Judd; Tim Rhodes; Lisa G Johnston; Lucy Platt; Violeta Andjelkovic; Danijela Simić; Boban Mugosa; Milena Simić; Sonja Zerjav; Ruth P Parry; John V Parry
Journal:  BMC Infect Dis       Date:  2009-02-09       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.